Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients (clinicaltrials.gov) - Sep 3, 2026 - P2 | N=108 | Recruiting | Sponsor: Aspeya, Inc. | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2026 ➔ Mar 2027
Trial completion date • Trial primary completion date • CNS Disorders • Migraine
|